CJC-1295 research guide for Central. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Central trying to locate CJC-1295, the first thing to know is that this compound is available only through an online research supply market. The core insight for Central researchers: sourcing CJC-1295 depends entirely on vendor quality evaluation, not geography — and the quality verification approach is universal across all locations. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. What follows is a practical research guide built specifically around CJC-1295, covering everything a Central researcher needs before placing a first order.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Central researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Evaluating CJC-1295 vendors begins with the COA: access the batch-specific certificate prior to buying, not after. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone provides no identity confirmation. Warning signs in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. For Central researchers making a first CJC-1295 purchase: verify the vendor against this framework, begin with a small order, and confirm the COA batch number matches your received product before use.
Order CJC-1295 — ships to Central
COA-verified · International tracking · Research grade
All use of CJC-1295 in Central or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should follow research laboratory protocols. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that rigorous vendor evaluation eliminates. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not a licensed human medication and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
